Two-Component Stapling of Biologically Active and Conformationally Constrained Peptides: Past, Present, and Future
MetadataShow full item record
Iegre, J., Gaynord, J., Robertson, N., Sore, H., Hyvönen, M., & Spring, D. (2018). Two-Component Stapling of Biologically Active and Conformationally Constrained Peptides: Past, Present, and Future. Advanced Therapeutics, 1 (7), 1800052-1800052. https://doi.org/10.1002/adtp.201800052
Peptides are an emerging class of therapeutics in the pharmaceutical world. Whilst small molecules have dominated the therapeutic landscape for decades, the design and application of peptide drugs is emerging among the pharmaceutical industries and academia. Although highly selective and eﬃcacious, peptides are characterized by poor pharmacokinetic properties and amelioration of their bioavailability remains a major hurdle. Incorporation of conformational constraints within the peptide (such as peptide stapling) has been extensively used to improve the bioavailability of these molecules; consequently, it is not surprising that a plethora of stapling techniques has been developed and has had a signiﬁcant impact on the development of peptide therapeutics. Among the numerous stapling techniques known, two-component methodologies allow facile and divergent functionalization of peptides. The authors have pioneered a stapling technique that makes use of the double Cu-catalyzed azide–alkyne cycloaddition between di-azido peptides and functionalized di-alkynyl staples. In recent years, the authors have created biologically active, conformationally constrained peptides functionalized with cell-penetrating peptides, ﬂuorescent tags, and photo cross-linking moieties, demonstrating the wide applicability of this methodology. Herein, the impact, advantages, limitations, and future applications of this technology and other two-component peptide stapling techniques on the development of clinically relevant peptides are highlighted.
This work was funded by the European Research Council under the European Union’s Seventh Framework Programme (FP7/2007-2013)/ERC grant agreement no. [279337/DOS] (to DRS) and the Wellcome Trust Strategic (090340/Z/09/Z)Award (to DRS and MH). Engineering and Physical Sciences Research Council, Biotechnology and Biological Sciences Research Council, Medical Research Council Royal Society.
Wellcome Trust (090340/Z/09/Z)
European Research Council (279337)
External DOI: https://doi.org/10.1002/adtp.201800052
This record's URL: https://www.repository.cam.ac.uk/handle/1810/283105